Tirzepatide (Mounjaro/Zepbound)

Tirzepatide, marketed as Mounjaro or Zepbound, is a prescription medication used to manage type 2 diabetes and aid in weight loss by mimicking gut hormones that regulate blood sugar and appetite. A study published in Pharmacoepidemiol Drug Saf in 2025 documented the use of compounded GLP-1 receptor agonists, including tirzepatide, in a large primary care dataset. The study found that patients using these medications had improved glycemic control and experienced weight loss, though the specific impact varied among individuals.

Tirzepatide connects to other nodes related to type 2 diabetes management, weight loss therapies, and GLP-1 receptor agonists. It also links to patient outcomes such as reduced HbA1c levels and decreased body mass index.

The evidence from a single study provides valuable insights but is limited in scope and may not capture all potential effects or long-term outcomes of tirzepatide use.

Sources

• Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset. (PMID:41024632)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._